Tumor Biology

, Volume 37, Issue 8, pp 10775–10784 | Cite as

In vitro evaluation of antitumoral efficacy of catalase in combination with traditional chemotherapeutic drugs against human lung adenocarcinoma cells

  • Valeska Aguiar de Oliveira
  • Leonardo Lisbôa da Motta
  • Marco Antônio De Bastiani
  • Fernanda Martins Lopes
  • Carolina Beatriz Müller
  • Bernardo Papini Gabiatti
  • Fernanda Stapenhorst França
  • Mauro Antônio Alves Castro
  • Fabio Klamt
Original Article


Lung cancer is the most lethal cancer-related disease worldwide. Since survival rates remain poor, there is an urgent need for more effective therapies that could increase the overall survival of lung cancer patients. Lung tumors exhibit increased levels of oxidative markers with altered levels of antioxidant defenses, and previous studies demonstrated that the overexpression of the antioxidant enzyme catalase (CAT) might control tumor proliferation and aggressiveness. Herein, we evaluated the effect of CAT treatment on the sensitivity of A549 human lung adenocarcinoma cells toward various anticancer treatments, aiming to establish the best drug combination for further therapeutic management of this disease. Exponentially growing A549 cells were treated with CAT alone or in combination with chemotherapeutic drugs (cisplatin, 5-fluorouracil, paclitaxel, daunorubicin, and hydroxyurea). CalcuSyn® software was used to assess CAT/drug interactions (synergism or antagonism). Growth inhibition, NFκB activation status, and redox parameters were also evaluated in CAT-treated A549 cells. CAT treatment caused a cytostatic effect, decreased NFκB activation, and modulated the redox parameters evaluated. CAT treatment exhibited a synergistic effect among most of the anticancer drugs tested, which is significantly correlated with an increased H2O2 production. Moreover, CAT combination caused an antagonism in paclitaxel anticancer effect. These data suggest that combining CAT (or CAT analogs) with traditional chemotherapeutic drugs, especially cisplatin, is a promising therapeutic strategy for the treatment of lung cancer.


Lung cancer A549 cells Catalase Anticancer drug combination Chemotherapy Drug synergism 



Brazilians funds MCT/CNPq Universal (470306/2011-4), PRONEX/FAPERGS (1000274), PRONEM/FAPERGS (11/2032-5), PqG/FAPERGS (2414-2551/12-8), MCT/CNPq INCT-TM (573671/2008-7), and FAPERGS/MS/CNPq/SESRS/PPSUS (1121-2551/13-8) provided the financial support without interference in the ongoing work.

Compliance with ethical standards

Conflicts of interest


Supplementary material

13277_2016_4973_Fig5_ESM.gif (435 kb)
Supplementary Fig. 1

(GIF 434 kb)

13277_2016_4973_MOESM1_ESM.tiff (2.9 mb)
High resolution image (TIFF 2.85 mb)


  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. doi: 10.3322/caac.21208.CrossRefPubMedGoogle Scholar
  2. 2.
    Mountzios G, Dimopoulos MA, Soria JC, Sanoudou D, Papadimitriou CA. Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: a review of published data. Crit Rev Oncol Hematol. 2010;75(2):94–109. doi: 10.1016/j.critrevonc.2009.10.002.CrossRefPubMedGoogle Scholar
  3. 3.
    Ko JH, Gu W, Lim I, Bang H, Ko EA, Zhou T. Ion channel gene expression in lung adenocarcinoma: potential role in prognosis and diagnosis. PLoS One. 2014;9(1):e86569. doi: 10.1371/journal.pone.0086569.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol. 2007;25:561–70. doi: 10.1200/JCO.2006.06.8015.CrossRefPubMedGoogle Scholar
  5. 5.
    Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist. 2008;13(1):5–13. doi: 10.1634/theoncologist.13-S1-5.CrossRefPubMedGoogle Scholar
  6. 6.
    Torigoe T, Izumi H, Ishiguchi H, Yoshida Y, Tanabe M, Yoshida T, et al. Cisplatin resistance and transcription factors. Curr Med Chem Anticancer Agents. 2005;5(1):15–27. doi: 10.2174/1568011053352587.CrossRefPubMedGoogle Scholar
  7. 7.
    Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer. 2011;71:3–10. doi: 10.1016/j.lungcan.2010.08.022.CrossRefPubMedGoogle Scholar
  8. 8.
    Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22(47):7265–79. doi: 10.1038/sj.onc.1206933.CrossRefPubMedGoogle Scholar
  9. 9.
    DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22(2):151–85. doi: 10.1016/S0167-6296(02)00126-1.CrossRefPubMedGoogle Scholar
  10. 10.
    Rahman I, Biswas SK, Kode A. Oxidant and antioxidant balance in the airways and airway diseases. Eur J Pharmacol. 2006;533(1–3):222–39. doi: 10.1016/j.ejphar.2005.12.087.CrossRefPubMedGoogle Scholar
  11. 11.
    Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006;160(1):1–40. doi: 10.1016/j.cbi.2005.12.009.CrossRefPubMedGoogle Scholar
  12. 12.
    Visconti R, Grieco D. New insights on oxidative stress in cancer. Curr Opin Drug Discov Dev. 2009;12(2):240–5.Google Scholar
  13. 13.
    Polytarchou C, Hatziapostolou M, Papadimitriou E. Hydrogen peroxide stimulates proliferation and migration of human prostate cancer cells through activation of activator protein-1 and up-regulation of the heparin affin regulatory peptide gene. J Biol Chem. 2005;280(49):40428–35. doi: 10.1074/jbc.M505120200.CrossRefPubMedGoogle Scholar
  14. 14.
    da Motta LL et al. Imbalance in redox status is associated with tumor aggressiveness and poor outcome in lung adenocarcinoma patients. J Cancer Res Clin Oncol. 2014;140(3):461–70. doi: 10.1007/s00432-014-1586-6.CrossRefGoogle Scholar
  15. 15.
    Nishikawa M, Hashida M, Takakura Y. Catalase delivery for inhibiting ROS-mediated tissue injury and tumor metastasis. Adv Drug Deliv Rev. 2009;61(4):319–26.CrossRefPubMedGoogle Scholar
  16. 16.
    Goh J, Enns L, Fatemie S, Hopkins H, Morton J, Pettan-Brewer C, et al. Mitochondrial targeted catalase suppresses invasive breast cancer in mice. BMC Cancer. 2011;11:191. doi: 10.1186/1471-2407-11-191.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 2006;1(3):1112–6. doi: 10.1038/nprot.2006.179.CrossRefPubMedGoogle Scholar
  18. 18.
    Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.CrossRefPubMedGoogle Scholar
  19. 19.
    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265–75.PubMedGoogle Scholar
  20. 20.
    Dresch MT, Rossato SB, Kappel VD, Biegelmeyer R, Hoff ML, Mayorga P, et al. Optimization and validation of an alternative method to evaluate total reactive antioxidant potential. Anal Biochem. 2009;385(1):107–14. doi: 10.1016/j.ab.2008.10.036.CrossRefPubMedGoogle Scholar
  21. 21.
    Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82(1):70–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Rahman I, Kode A, Biswas SK. Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat Protoc. 2007;1(6):3159–65. doi: 10.1038/nprot.2006.378.CrossRefGoogle Scholar
  23. 23.
    Zhou M, Diwu Z, Panchuk-Voloshina N, Haugland RP. A stable nonfluorescent derivative of resorufin for the fluorometric determination of trace hydrogen peroxide: applications in detecting the activity of phagocyte NADPH oxidase and other oxidases. Anal Biochem. 1997;253(2):162–8. doi: 10.1006/abio.1997.2391.CrossRefPubMedGoogle Scholar
  24. 24.
    Mohanty J, Jaffe JS, Schulman ES, Raible DG. A highly sensitive fluorescent micro-assay of H2O2 release from activated human leukocytes using a dihydroxyphenoxazine derivative. J Immunol Methods. 1997;202(2):133–41. doi: 10.1016/S0022-1759(96)00244-X.CrossRefPubMedGoogle Scholar
  25. 25.
    Chou T-C. Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method. Cancer Res. 2010;70(2):440–6. doi: 10.1158/0008-5472.CAN-09-1947.CrossRefPubMedGoogle Scholar
  26. 26.
    Chou T-C, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55.CrossRefPubMedGoogle Scholar
  27. 27.
    Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–94. doi: 10.4065/83.5.584.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Fisher AB. Redox signaling across cell membranes. Antioxid Redox Signal. 2009;11(6):1349–56. doi: 10.1089/ARS.2008.2378.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Ibañez IL, Policastro LL, Tropper I, Bracalente C, Palmieri MA, Rojas PA, et al. H2O2 scavenging inhibits G1/S transition by increasing nuclear levels of p27KIP1. Cancer Lett. 2011;305(1):58–68. doi: 10.1016/j.canlet.2011.02.026.CrossRefPubMedGoogle Scholar
  30. 30.
    Laurent A, Nicco C, Chéreau C, Goulvestre C, Alexandre J, Alves A, et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res. 2005;65(3):948–56.PubMedGoogle Scholar
  31. 31.
    Policastro L, Molinari B, Larcher F, Blanco P, Podhajcer OL, Costa CS, et al. Imbalance of antioxidant enzymes in tumor cells and inhibition of proliferation and malignant features by scavenging hydrogen peroxide. Mol Carcinog. 2004;39(2):103–13. doi: 10.1002/mc.20001.CrossRefPubMedGoogle Scholar
  32. 32.
    Sakon S, Xue X, Takekawa M, Sasazuki T, Okazaki T, Kojima Y, et al. NF-kappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J. 2003;22(15):3898–909. doi: 10.1093/emboj/cdg379.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer. 2005;5(4):297–309. doi: 10.1038/nrc1588.CrossRefPubMedGoogle Scholar
  34. 34.
    Bowie A, O’Neill LA. Oxidative stress and nuclear factor-kappaB activation: a reassessment of the evidence in the light of recent discoveries. Biochem Pharmacol. 2000;59(1):13–23. doi: 10.1016/S0006-2952(99)00296-8.CrossRefPubMedGoogle Scholar
  35. 35.
    Zanotto-Filho A, Delgado-Canedo A, Schroder R, Becker M, Klamt F, Moreira JC. The pharmacological NFkappaB inhibitors BAY117082 and MG132 induce cell arrest and apoptosis in leukemia cells through ROS-mitochondria pathway activation. Cancer Lett. 2010;288(2):192–203. doi: 10.1016/j.canlet.2009.06.038.CrossRefPubMedGoogle Scholar
  36. 36.
    Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol. 2007;8(1):49–62. doi: 10.1038/nrm2083.CrossRefPubMedGoogle Scholar
  37. 37.
    Zanotto-Filho A, Gelain DP, Schroder R, Souza LF, Pasquali MA, Klamt F, et al. The NF kappa B-mediated control of RS and JNK signaling in vitamin A-treated cells: duration of JNK-AP-1 pathway activation may determined cell death or proliferation. Biochem Pharmacol. 2009;77(7):1291–301. doi: 10.1016/j.bcp.2008.12.010.CrossRefPubMedGoogle Scholar
  38. 38.
    Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009;8(1):33–40. doi: 10.1038/nrd2781.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 1991;10(8):2247–58.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Godwin P, Baird AM, Heavey S, Barr M, O’Byrne K, Gately K. Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front Oncol. 2013;3:120. doi: 10.3389/fonc.2013.00120.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Yoo DG, Song YJ, Cho EJ, Lee SK, Park JB, Yu JH, et al. Alteration of APE1/ref-1 expression in non-small cell lung cancer: the implications of impaired extracellular superoxide dismutase and catalase antioxidant systems. Lung Cancer. 2008;60(2):277–84. doi: 10.1016/j.lungcan.2007.10.015.CrossRefPubMedGoogle Scholar
  42. 42.
    Wang D, Xiang DB, Yang X, Chen LS, Li MX, Zhong ZY, et al. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. Lung Cancer. 2009;66(3):298–304. doi: 10.1016/j.lungcan.2009.02.019.CrossRefPubMedGoogle Scholar
  43. 43.
    Scandalios JG. Oxidative stress: molecular perception and transduction of signals triggering antioxidant gene defenses. Braz J Med Biol Res. 2005;38(7):995–1014. doi: 10.1590/S0100-879X2005000700003.CrossRefPubMedGoogle Scholar
  44. 44.
    Ma SF, Nishikawa M, Hyoudou K, Takahashi R, Ikemura M, Kobayashi Y, et al. Combining cisplatin with cationized catalase decreases nephrotoxicity while improving antitumor activity. Kidney Int. 2007;72(12):1474–82. doi: 10.1038/ Scholar
  45. 45.
    Deng H, Shen W, Peng Y, Chen X, Yi G, Gao Z. Nanoparticulate peroxidase/catalase mimetic and its application. Chem Eur J. 2012;18(29):8906–11. doi: 10.1002/chem.201200643.CrossRefPubMedGoogle Scholar
  46. 46.
    Howard MD, Greineder CF, Hood ED, Muzykantov VR. Endothelial targeting of liposomes encapsulating SOD/catalase mimetic EUK-134 alleviates acute pulmonary inflammation. J Control Release. 2014;177:34–41. doi: 10.1016/j.jconrel.2013.12.035.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Giordano RJ, Edwards JK, Tuder RM, Arap W, Pasqualini R. Combinatorial ligand-directed lung targeting. Proc Am Thorac Soc. 2009;6(5):411–5. doi: 10.1513/pats.200903-014AW.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Valeska Aguiar de Oliveira
    • 1
    • 2
  • Leonardo Lisbôa da Motta
    • 1
    • 2
  • Marco Antônio De Bastiani
    • 1
    • 2
  • Fernanda Martins Lopes
    • 1
    • 2
  • Carolina Beatriz Müller
    • 1
    • 2
  • Bernardo Papini Gabiatti
    • 1
  • Fernanda Stapenhorst França
    • 1
  • Mauro Antônio Alves Castro
    • 2
    • 3
  • Fabio Klamt
    • 1
    • 2
  1. 1.Laboratory of Cellular Biochemistry, Departamento de BioquímicaICBS/ Universidade Federal do Rio Grande do Sul (UFRGS)Porto AlegreBrazil
  2. 2.National Institutes of Science & Technology – Translational Medicine (INCT-TM)Porto AlegreBrazil
  3. 3.Laboratory of BioinformaticsProfessional and Technological Education Sector, Centro Politécnico, UFPRCuritibaBrazil

Personalised recommendations